<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK424403" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK424403/" /><meta name="ncbi_pagename" content="Beta-Propeller Protein-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Beta-Propeller Protein-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Beta-Propeller Protein-Associated Neurodegeneration" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/02/16" /><meta name="citation_author" content="Allison Gregory" /><meta name="citation_author" content="Manju A Kurian" /><meta name="citation_author" content="Tobias Haack" /><meta name="citation_author" content="Susan J Hayflick" /><meta name="citation_author" content="Penelope Hogarth" /><meta name="citation_pmid" content="28211668" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK424403/" /><meta name="citation_keywords" content="BPAN" /><meta name="citation_keywords" content="Neurodegeneration with Brain Iron Accumulation 5 (NBIA5)" /><meta name="citation_keywords" content="BPAN" /><meta name="citation_keywords" content="Neurodegeneration with Brain Iron Accumulation 5 (NBIA5)" /><meta name="citation_keywords" content="WD repeat domain phosphoinositide-interacting protein 4" /><meta name="citation_keywords" content="WDR45" /><meta name="citation_keywords" content="Beta-Propeller Protein-Associated Neurodegeneration" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Beta-Propeller Protein-Associated Neurodegeneration" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Allison Gregory" /><meta name="DC.Contributor" content="Manju A Kurian" /><meta name="DC.Contributor" content="Tobias Haack" /><meta name="DC.Contributor" content="Susan J Hayflick" /><meta name="DC.Contributor" content="Penelope Hogarth" /><meta name="DC.Date" content="2017/02/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK424403/" /><meta name="description" content="Beta-propeller protein-associated neurodegeneration (BPAN) is typically characterized by early-onset seizures, infantile-onset developmental delay, intellectual disability, absent to limited expressive language, motor dysfunction (ataxia), and abnormal behaviors often similar to autism spectrum disorder. Seizure types including generalized (absence, tonic, atonic, tonic-clonic and myoclonic), focal with impaired consciousness, and epileptic spasms, as well as epileptic syndromes (West syndrome and Lennox-Gastaut syndrome) can be seen. With age seizures tend to resolve or become less prominent, whereas cognitive decline and movement disorders (progressive parkinsonism and dystonia) emerge as characteristic findings." /><meta name="og:title" content="Beta-Propeller Protein-Associated Neurodegeneration" /><meta name="og:type" content="book" /><meta name="og:description" content="Beta-propeller protein-associated neurodegeneration (BPAN) is typically characterized by early-onset seizures, infantile-onset developmental delay, intellectual disability, absent to limited expressive language, motor dysfunction (ataxia), and abnormal behaviors often similar to autism spectrum disorder. Seizure types including generalized (absence, tonic, atonic, tonic-clonic and myoclonic), focal with impaired consciousness, and epileptic spasms, as well as epileptic syndromes (West syndrome and Lennox-Gastaut syndrome) can be seen. With age seizures tend to resolve or become less prominent, whereas cognitive decline and movement disorders (progressive parkinsonism and dystonia) emerge as characteristic findings." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK424403/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/bpan/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK424403/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DF4AFE03F1C11000000000A5403A0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK424403_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK424403_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bvd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/b-thal/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK424403_"><span class="title" itemprop="name">Beta-Propeller Protein-Associated Neurodegeneration</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: BPAN, Neurodegeneration with Brain Iron Accumulation 5 (NBIA5)</div><p class="contrib-group"><span itemprop="author">Allison Gregory</span>, MS, <span itemprop="author">Manju A Kurian</span>, PhD, <span itemprop="author">Tobias Haack</span>, MD, <span itemprop="author">Susan J Hayflick</span>, MD, and <span itemprop="author">Penelope Hogarth</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK424403_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK424403_ai__"><div class="contrib half_rhythm"><span itemprop="author">Allison Gregory</span>, MS<div class="affiliation small">Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@ayrogerg" class="oemail">ude.usho@ayrogerg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Manju A Kurian</span>, PhD<div class="affiliation small">University College London<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@nairuk.ujnam" class="oemail">ku.ca.lcu@nairuk.ujnam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Tobias Haack</span>, MD<div class="affiliation small">Helmholtz Zentrum &#x00026; Technische Universit&#x000e4;t M&#x000fc;nchen<br />Munich, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.nehcneum-ztlohmleh@kcaah.saibot" class="oemail">ed.nehcneum-ztlohmleh@kcaah.saibot</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Susan J Hayflick</span>, MD<div class="affiliation small">Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@kcilfyah" class="oemail">ude.usho@kcilfyah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Penelope Hogarth</span>, MD<div class="affiliation small">Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@phtragoh" class="oemail">ude.usho@phtragoh</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 16, 2017</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="bpan.Summary" itemprop="description"><h2 id="_bpan_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Beta-propeller protein-associated neurodegeneration (BPAN) is typically characterized by early-onset seizures, infantile-onset developmental delay, intellectual disability, absent to limited expressive language, motor dysfunction (ataxia), and abnormal behaviors often similar to autism spectrum disorder. Seizure types including generalized (absence, tonic, atonic, tonic-clonic and myoclonic), focal with impaired consciousness, and epileptic spasms, as well as epileptic syndromes (West syndrome and Lennox-Gastaut syndrome) can be seen. With age seizures tend to resolve or become less prominent, whereas cognitive decline and movement disorders (progressive parkinsonism and dystonia) emerge as characteristic findings.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of BPAN is established by identifying on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>:</p><ul><li class="half_rhythm"><div>In females. A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>;</div></li><li class="half_rhythm"><div>In males. Either a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or partial <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>WDR45</i>.</div></li></ul><p>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been reported in rare females (and possibly in 1 male).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Seizure management, tailored to the individual, may include antiepileptic drugs (AEDs), ketogenic diet, and/or vagus nerve stimulation. Developmental delays and intellectual disability are managed in infancy and early childhood with early intervention programs and in school-age children with individual education programs. Consultation with a developmental pediatrician to ensure appropriate services is recommended. Discussion about transition plans including financial, vocation/employment, and medical arrangements should begin at age 12 years. Consider alternative means of communication, such as an Augmentative and Alternative Communication (AAC) program, for individuals who have expressive language difficulties. Motor dysfunction in childhood is managed with physical therapy to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation). Occupational therapy may aid in writing, feeding, grooming, and dressing. For those with feeding difficulties, feeding therapy may be considered. For individuals with social/behavioral difficulties, consider applied behavior analysis (ABA) therapy, medical management strategies in conjunction with a developmental specialist, and pediatric psychiatry consultation to address aggressive or destructive behaviors. In adolescents/adults with parkinsonism, dystonia, and spasticity, the usual pharmacologic agents can be considered with the caveat that these therapies could exacerbate the cognitive deficits that also occur in this age group. Children with abnormal behaviors may qualify for and benefit from interventions used in treatment of autism spectrum disorder.</p><p><i>Surveillance:</i> Routine follow up by a neurologist for medication management and interval assessment of ambulation, seizure activity, speech, and evidence of swallowing dysfunction. For those receiving dopaminergic drugs (for parkinsonism), monitor for adverse neuropsychiatric effects and disabling motor fluctuations and dyskinesias.</p><p><i>Pregnancy management:</i> Use of AEDs during pregnancy for women with a seizure disorder is generally recommended, despite an increased risk for adverse fetal outcome associated with some AEDs. Discussion of the risks and benefits of using a given antiepileptic medication during pregnancy ideally should take place prior to conception. Transitioning to a lower-risk medication may be possible.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>BPAN is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner; to date, most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been female, and the vast majority are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) resulting from a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The exceptions include two <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases, one with presumed maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> and one with transmission of a <i>WDR45</i> pathogenic variant by a phenotypically normal mother who demonstrated significantly skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. Females with the typical BPAN <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> do not reproduce. In rare instances, a female who is mildly affected may reproduce. Affected males do not reproduce. Once the <i>WDR45</i> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for BPAN are possible.</p></div></div><div id="bpan.Diagnosis"><h2 id="_bpan_Diagnosis_">Diagnosis</h2><p>No formal diagnostic criteria for beta-propeller protein-associated neurodegeneration (BPAN) have been published.</p><div id="bpan.Suggestive_Findings"><h3>Suggestive Findings</h3><p>BPAN <b>should be suspected</b> in an individual with the following <a href="#bpan.Clinical_Findings">clinical</a> and <a href="#bpan.MRI_Findings">MRI</a> findings.</p><div id="bpan.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Seizures</b> characterized by the following:</p><ul><li class="half_rhythm"><div><b>Features</b></div><ul><li class="half_rhythm"><div>Onset in early childhood</div></li><li class="half_rhythm"><div>Development of multiple seizure types</div></li><li class="half_rhythm"><div>Seizures worse in early childhood, lessening with age</div></li></ul></li><li class="half_rhythm"><div><b>Types</b></div><ul><li class="half_rhythm"><div>Generalized (absence, tonic, atonic, tonic-clonic and myoclonic)</div></li><li class="half_rhythm"><div>Focal seizures with impaired consciousness</div></li><li class="half_rhythm"><div>Epileptic spasms</div></li></ul></li><li class="half_rhythm"><div><b>Syndromes</b></div><ul><li class="half_rhythm"><div>West syndrome</div></li><li class="half_rhythm"><div>Lennox-Gastaut syndrome</div></li><li class="half_rhythm"><div>Early-onset epilepsy with intellectual disability</div></li></ul></li></ul><p><b>Developmental delay / intellectual disability</b> (with minimal or absent expressive language) that is relatively stable in childhood, followed by progressive loss of cognitive function beginning in adolescence or early adulthood</p><p><b>Progressive parkinsonism and dystonia</b>, beginning in adolescence or early adulthood</p><p><b>Abnormal behaviors</b> that overlap with <a href="/books/n/gene/rett/">Rett syndrome</a>, including stereotypic hand movements, bruxism when awake, and abnormal sleep patterns</p></div><div id="bpan.MRI_Findings"><h4>MRI Findings</h4><p>Nonspecific hypomyelination and thin corpus callosum are seen in early childhood [<a class="bk_pop" href="#bpan.REF.rathore.2014.574">Rathore et al 2014</a>; <a class="bk_pop" href="#bpan.REF.khalifa.2015.381">Khalifa &#x00026; Naffaa 2015</a>; Hogarth, unpublished data] and evolve to highly specific signal abnormalities in later childhood, adolescence, or early adulthood:</p><ul><li class="half_rhythm"><div>T<sub>2</sub>-weighted or iron-sensitive sequences reveal hypointense signal in the substantia nigra and globus pallidus (<a class="figpopup" href="/books/NBK424403/figure/bpan.F1/?report=objectonly" target="object" rid-figpopup="figbpanF1" rid-ob="figobbpanF1">Figure 1</a>). Note: Although less prominent than in older individuals, this finding is documented in children as young as age five years [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>; <a class="bk_pop" href="#bpan.REF.ichinose.2014.175">Ichinose et al 2014</a>; Hogarth, unpublished data].</div></li><li class="half_rhythm"><div>T<sub>1</sub>-weighted sequences show a hyperintense "halo" surrounding a central linear region of signal hypointensity within the substantia nigra and cerebral peduncles (<a class="figpopup" href="/books/NBK424403/figure/bpan.F2/?report=objectonly" target="object" rid-figpopup="figbpanF2" rid-ob="figobbpanF2">Figure 2</a>).</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbpanF1" co-legend-rid="figlgndbpanF1"><a href="/books/NBK424403/figure/bpan.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figbpanF1" rid-ob="figobbpanF1"><img class="small-thumb" src="/books/NBK424403/bin/bpan-Image001.gif" src-large="/books/NBK424403/bin/bpan-Image001.jpg" alt="Figure 1. . T2-weighted sequences demonstrating globus pallidus hypointensity (A) and hypointensity of the substantia nigra (B)." /></a><div class="icnblk_cntnt" id="figlgndbpanF1"><h4 id="bpan.F1"><a href="/books/NBK424403/figure/bpan.F1/?report=objectonly" target="object" rid-ob="figobbpanF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">T<sub>2</sub>-weighted sequences demonstrating globus pallidus hypointensity (A) and hypointensity of the substantia nigra (B). In BPAN, the substantia nigra is usually more hypointense relative to the globus pallidus, indicating higher levels of iron. Note: The <a href="/books/NBK424403/figure/bpan.F1/?report=objectonly" target="object" rid-ob="figobbpanF1">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbpanF2" co-legend-rid="figlgndbpanF2"><a href="/books/NBK424403/figure/bpan.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figbpanF2" rid-ob="figobbpanF2"><img class="small-thumb" src="/books/NBK424403/bin/bpan-Image002.gif" src-large="/books/NBK424403/bin/bpan-Image002.jpg" alt="Figure 2. . T1 imaging demonstrates the hyperintense halo surrounding a central linear band of hypointensity in the substantia nigra and cerebral peduncles." /></a><div class="icnblk_cntnt" id="figlgndbpanF2"><h4 id="bpan.F2"><a href="/books/NBK424403/figure/bpan.F2/?report=objectonly" target="object" rid-ob="figobbpanF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">T<sub>1</sub> imaging demonstrates the hyperintense halo surrounding a central linear band of hypointensity in the substantia nigra and cerebral peduncles. </p></div></div><p>Cerebellar or cerebral atrophy may also be present at any age.</p></div></div><div id="bpan.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of BPAN <b>is usually established in</b>
<b>a</b>
<b>female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>WDR45</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK424403/table/bpan.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figbpanTmoleculargenetictestingusedin" rid-ob="figobbpanTmoleculargenetictestingusedin">Table 1</a>). Note: Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been documented in leukocyte DNA of healthy mothers of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male sibs [<a class="bk_pop" href="#bpan.REF.dufke.2014">Dufke et al 2014</a>] and affected male/female sibs [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>] (see <a href="#bpan.Genetic_Counseling">Genetic Counseling</a> and <a href="#bpan.Molecular_Genetics">Molecular Genetics</a>).</p><p>The diagnosis of BPAN <b>is established in</b>
<b>a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>WDR45</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK424403/table/bpan.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figbpanTmoleculargenetictestingusedin" rid-ob="figobbpanTmoleculargenetictestingusedin">Table 1</a>). Of note:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> 19.9-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that includes part of <i>WDR45</i>, all of an adjacent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, and part of a third gene has been reported in a severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male [<a class="bk_pop" href="#bpan.REF.abidi.2016.615">Abidi et al 2016</a>] (see <a href="#bpan.Molecular_Genetics">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div>In three families with recurrence of BPAN in sibs, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males had inherited a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#bpan.REF.dufke.2014">Dufke et al 2014</a>, <a class="bk_pop" href="#bpan.REF.nakashima.2016.653">Nakashima et al 2016</a>, <a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>] (see <a href="#bpan.Molecular_Genetics">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div>Apparent <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a male has been described [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>] (see <a href="#bpan.Genetic_Counseling">Genetic Counseling</a> and <a href="#bpan.Molecular_Genetics">Molecular Genetics</a>).</div></li></ul><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or single-gene testing) and <b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing may not. In some cases, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of BPAN may be distinctive enough to warrant single gene-targeted testing (see <b>Option 1</b>), whereas those with a phenotype that is indistinguishable from many other inherited disorders with intellectual disability and neurologic findings (including seizures) are more likely to be diagnosed using genomic testing (see <b>Option 2</b>).</p><p><b>Option 1.</b>
<b>Gene-targeted testing.</b> When the clinical and MRI findings suggest the diagnosis of BPAN, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to consider includes the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>WDR45</i> is performed first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> could be considered.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>WDR45</i> and other genes of interest (see <a href="#bpan.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) For this disorder a multigene panel that also includes <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is recommended (see <a class="figpopup" href="/books/NBK424403/table/bpan.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figbpanTmoleculargenetictestingusedin" rid-ob="figobbpanTmoleculargenetictestingusedin">Table 1</a>). (5) If <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> is suspected, discuss with the testing laboratory the ability of their methodology to detect mosaicism.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p><b>Option 2. Genomic testing.</b> When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders with intellectual disability and neurologic findings (including seizures), <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to consider includes the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>. Note: These methods are generally suboptimal for detection of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> due to insufficient read depth of coverage.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> for inherited disorders with intellectual disability and neurologic findings</div></li></ul><div id="bpan.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Beta Propeller Protein-Associated Neurodegeneration (BPAN)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK424403/table/bpan.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bpan.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>WDR45</i></td><td headers="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_bpan.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bpan.TF.1.1"><p class="no_margin">See <a href="/books/NBK424403/#bpan.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="bpan.TF.1.2"><p class="no_margin">See <a href="#bpan.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="bpan.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="bpan.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a></p></div></dd><dt>5. </dt><dd><div id="bpan.TF.1.5"><p class="no_margin">The failure to detect a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> using sequence-based testing could be due to <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> in a male or female or &#x02013; theoretically &#x02013; a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in a female (not reported in a female to date).</p></div></dd><dt>6. </dt><dd><div id="bpan.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#bpan.REF.pontkingdon.2012.41">Pont-Kingdon et al [2012]</a></p></div></dd><dt>7. </dt><dd><div id="bpan.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="bpan.TF.1.8"><p class="no_margin">One <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> 19.9-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that includes part of <i>WDR45</i> has been reported [<a class="bk_pop" href="#bpan.REF.abidi.2016.615">Abidi et al 2016</a>].</p></div></dd></dl></div></div></div></div></div><div id="bpan.Clinical_Characteristics"><h2 id="_bpan_Clinical_Characteristics_">Clinical Characteristics</h2><div id="bpan.Clinical_Description"><h3>Clinical Description</h3><p>Beta-propeller protein-associated neurodegeneration (BPAN) typically presents with seizures, infantile-onset developmental delay, intellectual disability, absent to limited expressive language, and abnormal behaviors with Rett syndrome-like features. During adolescence and early adulthood (mean age 25 years; range 15-37 years) some of the hallmark childhood features (e.g., seizures) resolve or become less prominent, while cognitive decline and progressive parkinsonism and dystonia emerge as characteristic findings [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>, <a class="bk_pop" href="#bpan.REF.nishioka.2015.2004.e9">Nishioka et al 2015</a>].</p><p>The majority of individuals with BPAN are female; however, some males have been reported. Significant phenotypic variability is observed in both males and females.</p><p>With increasing use of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing, individuals with BPAN now tend to be identified at younger ages than those originally described by <a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al [2012]</a>.</p><div id="bpan.Core_Clinical_Features"><h4>Core Clinical Features</h4><p><b>Seizures</b> are common during childhood, often starting as febrile seizures [<a class="bk_pop" href="#bpan.REF.nishioka.2015.2004.e9">Nishioka et al 2015</a>]. Seizures are frequently multiform and include focal seizures with impaired consciousness, epileptic spasms [Hogarth, personal communication], and generalized seizures, including absence, atonic, myoclonic, and tonic-clonic [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>].</p><p>One young boy included in a cohort of children with early-onset epileptic encephalopathy had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>WDR45</i> and two contiguous genes (<i>CCDC120</i> and <i>PRAF2</i>) and clinical findings consistent with BPAN (brain iron accumulation, dystonia, and spastic tetraparesis) [<a class="bk_pop" href="#bpan.REF.abidi.2016.615">Abidi et al 2016</a>].</p><p>Although seizures often require pharmacologic treatment and may be intractable, they often resolve or become less prominent with age.</p><p><b>Developmental delay / intellectual disability.</b> Individuals with BPAN typically have developmental delay as children. The majority of children with BPAN have no expressive language; some develop limited language. Rarely, girls with BPAN can be high functioning with normal or nearly normal language development and less severe learning disabilities [<a class="bk_pop" href="#bpan.REF.long.2015.e714">Long et al 2015</a>].</p><p>Onset of progressive dementia occurs between adolescence and early to middle adulthood (mean age 25 years; range 15-37 years) [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>]. Similar neurologic decline was observed in seven <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> Japanese women between ages 29 to 39 years [<a class="bk_pop" href="#bpan.REF.nishioka.2015.2004.e9">Nishioka et al 2015</a>].</p><p>In some instances, parents of children with BPAN have reported regression during early childhood; however, it is not clear whether this is due to the underlying disease, unrecognized seizures, or both [Hogarth, personal communication]. The aggressive epilepsy profile eventually seen in some children with BPAN may itself contribute to cognitive dysfunction, as in other epileptic encephalopathies.</p><p><b>Motor dysfunction.</b> Children are typically clumsy and have a broad-based or ataxic gait. Some never learn to walk; others who achieve walking eventually become non-ambulatory. Some have mild spasticity that generally does not require treatment.</p><p>Fine motor skills are also impaired. Some also have limited purposeful hand use (reminiscent of <a href="/books/n/gene/rett/">Rett syndrome</a>) that can contribute to functional impairments such as difficulty with dressing and use of utensils.</p><p><b>The neurologic deterioration</b> that occurs during adolescence and early to middle adulthood also includes onset of movement disorders, dystonia, and parkinsonism [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>, <a class="bk_pop" href="#bpan.REF.nishioka.2015.2004.e9">Nishioka et al 2015</a>].</p><p>Dystonia often starts in the upper extremities.</p><p>Parkinsonism is characterized by prominent bradykinesia, rigidity, freezing of gait, and postural instability. Tremor is not as common as in other forms of parkinsonism.</p><p><b>Abnormal behaviors</b> that overlap with Rett syndrome include lack of purposeful hand movements, stereotypic hand movements such as repetitive midline hand-wringing, bruxism when awake, abnormal sleep patterns, features of autism spectrum disorder, and diminished response to pain [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>, <a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>, <a class="bk_pop" href="#bpan.REF.ohba.2014.292">Ohba et al 2014</a>, <a class="bk_pop" href="#bpan.REF.khalifa.2015.381">Khalifa &#x00026; Naffaa 2015</a>]. Some young girls have been noted to have episodes of deep breathing during waking hours [Authors, personal observation]. Several individuals with BPAN have been diagnosed with autism spectrum disorder &#x02013; due in part to their limited language and social skills [<a class="bk_pop" href="#bpan.REF.verhoeven.2014.332">Verhoeven et al 2014</a>].</p></div><div id="bpan.Other_Features"><h4>Other Features</h4><p><b>Disordered sleep.</b> Many families report that because their young children with BPAN have difficulty falling asleep and staying asleep, they sleep for only short periods of time. When performed, sleep studies revealed shortened mean sleep latency and abnormal REM sleep, hypersomnolence, hyposomnolence, and "dance-like" movements of the extremities with sleep onset [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>]. Unrecognized nocturnal seizure activity may contribute to abnormal sleep patterns.</p><p>Some adults with BPAN continue to have sleep difficulties or develop new manifestations such as waking and vocalizing during the night. Two of seven Japanese women had sleep problems as adults [<a class="bk_pop" href="#bpan.REF.nishioka.2015.2004.e9">Nishioka et al 2015</a>].</p><p><b>Ophthalmologic findings</b> including bilateral partial retinal colobomas, high myopia, astigmatism with myopia, spontaneous retinal detachment, and patchy loss of the pupillary ruff were observed in seven of 23 individuals [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>].</p><p>Bilateral optic atrophy has been described in one individual who also had bilateral sensorineural hearing loss [<a class="bk_pop" href="#bpan.REF.rathore.2014.574">Rathore et al 2014</a>].</p><p><b>Feeding and nutritional issues</b>. Some infants and young children have feeding difficulties, most commonly texture sensitivity, oropharyngeal dysfunction, and aspiration. In some instances, GE reflux in young children has also required medical management. The neurologic deterioration that occurs in adolescence to early or middle adulthood frequently involves progressive feeding difficulty related to cognitive decline, dystonia, and parkinsonism and often results in significant weight loss.</p><p><b>Neuropathologic features.</b> Findings in a woman who died from pneumonia at age 27 years included mild cerebellar atrophy, thinned cerebral peduncles, and dark gray-brown appearance of the substantia nigra and (to a lesser extent) the globus pallidus. The substantia nigra and globus pallidus stained strongly for iron and demonstrated numerous axonal spheroids &#x02013; both findings consistent with the pathology of other types of neurodegeneration with brain iron accumulation. Numerous tau-positive neurofibrillary tangles were seen in several regions; no beta-amyloid plaques or Lewy bodies were observed [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>].</p><p>In a second, more advanced case the findings were similar, but with more extensive neuronal loss and tau pathology [<a class="bk_pop" href="#bpan.REF.paudel.2015.39">Paudel et al 2015</a>]. Recent, unpublished findings by the authors suggest a more complex pathology.</p></div><div id="bpan.BPAN_in_Affected_Males_and_Females"><h4>BPAN in Affected Males and Females</h4><p>Although <i>WDR45</i> is <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> and in females is subject to <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, the clinical features of BPAN follow a pattern that is somewhat atypical for an X-linked disorder: while there are far fewer <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males than females, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is similar in the two sexes.</p><p>In the original report of 20 individuals, the three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males had pathogenic variants predicted to render the protein nonfunctional (all frameshifts leading to premature stop codons). One of these males had evidence suggestive of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>]. A hypothesis of somatic mosaicism of a <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can explain both the viability of these males and the similarity of their <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to that of affected <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females who are functionally mosaic due to <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>, <a class="bk_pop" href="#bpan.REF.saitsu.2013.445">Saitsu et al 2013</a>].</p><p>Males with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>WDR45</i> were originally predicted to be non-viable, but five such males from three families have since been reported [<a class="bk_pop" href="#bpan.REF.dufke.2014">Dufke et al 2014</a>, <a class="bk_pop" href="#bpan.REF.nakashima.2016.653">Nakashima et al 2016</a>, <a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>]. Two families had <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants while the other had a 3-bp <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>.</p><p>The overall paucity of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males relative to females suggests that <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants are rare in males and that affected male conceptuses are less likely to survive than female conceptuses. In two sets of male-female sibs with inherited <i>WDR45</i> pathogenic variants, the males were more severely affected than the females [<a class="bk_pop" href="#bpan.REF.nakashima.2016.653">Nakashima et al 2016</a>, <a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>]; of note, one female showed strongly skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> with the abnormal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> being preferentially active [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>].</p><p>In summary, the following factors are all proposed to contribute to the variability in <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and to the predominance of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females relative to males:</p><ul><li class="half_rhythm"><div>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in both sexes</div></li><li class="half_rhythm"><div>Skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> in females</div></li><li class="half_rhythm"><div>The specific type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div></li></ul></div></div><div id="bpan.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Germline <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants are predicted to lead to non-viable males. The vast majority of pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> and <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a>.</p></div><div id="bpan.Nomenclature"><h3>Nomenclature</h3><p>The BPAN <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> was recognized in the initial (2002) version of <a href="/books/n/gene/pkan/">Pantothenate Kinase-Associated Neurodegeneration</a> and in <a class="bk_pop" href="#bpan.REF.gregory.2009.73">Gregory et al [2009]</a>; however, naming it in a manner consistent with other forms of neurodegeneration with brain iron accumulation (NBIA) had to await discovery of the associated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p>Although referenced in the literature, the term SENDA (static encephalopathy with neurodegeneration in adulthood) is no longer favored [<a class="bk_pop" href="#bpan.REF.gregory.2011.254">Gregory &#x00026; Hayflick 2011</a>, <a class="bk_pop" href="#bpan.REF.kruer.2012.407">Kruer et al 2012</a>].</p></div><div id="bpan.Prevalence"><h3>Prevalence</h3><p>Similar to other forms of <a href="/books/n/gene/nbia-ov/">neurodegeneration with brain iron accumulation</a> (NBIA), BPAN is an ultra-rare disorder. Approximately 45 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported in the literature to date.</p></div></div><div id="bpan.Genetically_Related_Allelic_Disorde"><h2 id="_bpan_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>WDR45</i>.</p></div><div id="bpan.Differential_Diagnosis"><h2 id="_bpan_Differential_Diagnosis_">Differential Diagnosis</h2><p>In childhood, the core clinical features of BPAN &#x02013; seizures, developmental delay / intellectual disability, movement disorders, and behavioral abnormalities &#x02013; are highly variable between individuals and lack specificity, overlapping with many other genetic and <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> (non-genetic) disorders. Early in the disease course, imaging abnormalities are similarly nonspecific, particularly if iron-sensitive sequences are not employed. The differential diagnosis at this stage is therefore broad, and includes <a href="/books/n/gene/rett/">Rett syndrome</a>, <a href="/books/n/gene/angelman/">Angelman syndrome</a>, alpha-fucosidosis, and the epileptic encephalopathies of infancy and childhood:</p><ul><li class="half_rhythm"><div class="half_rhythm">Dravet syndrome (see <a href="/books/n/gene/gefs/"><i>SCN1A</i> Seizure Disorders</a>)</div></li><li class="half_rhythm"><div class="half_rhythm">West syndrome</div></li><li class="half_rhythm"><div class="half_rhythm">Lennox-Gastaut syndrome</div></li><li class="half_rhythm"><div class="half_rhythm">Epilepsy with electrical status during slow-wave sleep</div></li><li class="half_rhythm"><div class="half_rhythm">Gelastic epilepsy</div></li><li class="half_rhythm"><div class="half_rhythm">Kozhevnikov-Rasmussen syndrome</div></li><li class="half_rhythm"><div class="half_rhythm">Landau-Kleffner syndrome</div></li><li class="half_rhythm"><div class="half_rhythm">Early-infantile epileptic encephalopathy (See <a href="http://omim.org/phenotypicSeries/PS308350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epileptic encephalopathy, early infantile: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.)</div><div class="half_rhythm">Note: Like BPAN, the epileptic encephalopathies present with multiple seizure types in the first months or years of life and are associated with severe neurocognitive deficits. Note that specific eponyms are applied to a particular clinical and electrographic profile and do not imply a specific etiology: many genetic and non-genetic etiologies can result in a given epilepsy syndrome.</div></li></ul><p>If imaging reveals basal ganglia hypointensity on iron-sensitive sequences, the differential diagnosis narrows to the NBIA disorders and imaging phenocopies. These disorders can generally be distinguished from BPAN and each other by specific clinical and imaging features. See <a href="/books/n/gene/nbia-ov/">Neurodegeneration with Brain Iron Accumulation Disorders Overview</a>.</p><p>Clinical features and the presence of high brain iron on MRI distinguish BPAN from other forms of childhood- or early adult-onset dystonia-parkinsonism, such as <a href="/books/n/gene/pink1-pd/"><i>PINK1-</i>related Parkinson disease</a> and <a href="/books/n/gene/jpd/">parkin-type Parkinson disease</a>.</p><p>Neuropathologic findings (see Clinical Description, <a href="#bpan.Other_Features">Other Features</a>) can help distinguish BPAN from other forms of NBIA.</p><ul><li class="half_rhythm"><div>In BPAN the pathologic changes found in the substantia nigra dominate those found in the globus pallidus (consistent with MRI findings), in contrast to other forms of NBIA in which the globus pallidus is more involved.</div></li><li class="half_rhythm"><div>BPAN can be distinguished by the lack of &#x003b1;-synuclein pathology that is abundant in MPAN and PLAN.</div></li></ul></div><div id="bpan.Management"><h2 id="_bpan_Management_">Management</h2><div id="bpan.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with beta-propeller protein-associated neurodegeneration (BPAN), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Complete neurologic examination and developmental assessment including evaluation of motor function, speech/language, swallowing, and sleep</div></li><li class="half_rhythm"><div>EEG monitoring, including sleep EEG, for any child with features (by history or observation) to suggest overt or occult seizures. Early referral to a neurology epilepsy sub-specialist is recommended if hypsarrhythmia or another aggressive electrographic pattern is found on EEG.</div></li><li class="half_rhythm"><div>Assessments by specialists in physical, occupational, and/or speech therapy</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Assessment of nutrition by a nutritionist or dietician</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="bpan.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Seizures.</b> As seizure severity and complexity varies widely, management should be tailored to the individual.</p><p>Some children with BPAN may have no evidence of seizures or experience only rare febrile events and require no ongoing pharmacologic intervention. Others have severe, refractory epilepsy with multiple seizure types warranting the involvement of specialists in pediatric epilepsy and consideration of multiple therapeutic modalities, including antiepileptic drugs (AEDs), ketogenic diet, and/or vagus nerve stimulation.</p><p>Short-term treatment with ACTH, prednisolone, or vigabatrin should be considered early in the care of a child with epileptic spasms, based on the guidelines in the US consensus report from the International League Against Epilepsy [<a class="bk_pop" href="#bpan.REF.pellock.2010.2175">Pellock et al 2010</a>].</p><p>Education of parents regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for parents or caregivers of children diagnosed with epilepsy, see <a href="http://www.epilepsy.com/sites/core/files/atoms/files/English_Toolkit_updated%202014.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><u>Epilepsy</u> &#x00026; My Child Toolkit</a>.</p><div id="bpan.Developmental_Delay__Intellectual_D"><h4>Developmental Delay / Intellectual Disability</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a nationwide federally funded program available in all states.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. An evaluation will occur before placement to determine needed services and therapies and will be subsequently written into an individualized education plan (IEP).</p><p><b>Ages 5-21 years.</b> In the US, an IEP should be developed by the local public school district based on each individuals' level of function. Affected children are permitted to remain in the public school district until age 21.</p><p><b>All ages.</b> In the US, individuals are protected under IDEA (Individuals with Disabilities Education Act) and should receive <b>free and appropriate public education</b> in the <b>least restricted environment</b>.</p><p>Consultation with a developmental pediatrician is recommended to ensure that appropriate community, state, and educational agencies are involved and to support parents in maximizing quality of life. Developmental pediatricians can also provide assistance with transition to adulthood.</p><p>Consideration of private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p><p>In the US:</p><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="bpan.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction.</b> Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).</p><p>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers)</p><p>For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, Botox<sup>&#x000ae;</sup> anti-parkinsonian medications, or orthopedic procedures.</p><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function (e.g., writing, feeding, grooming, and dressing).</p><p><b>Oral motor dysfunction.</b> Assuming that the indvidual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who have difficulty feeding due to poor oral motor control.</p><p><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC] for individuals who have expressive language difficulties.</p><p><b>Parkinsonism.</b> Involvement of a neurologist specializing in movement disorders may be helpful once parkinsonism emerges in adolescents/adults.</p><p>In the treatment of parkinsonism, dystonia, and spasticity the usual pharmacologic agents can be considered with the caveat that these therapies could exacerbate the cognitive deficits that also occur in this age group.</p><p>Pharmacologic treatment of parkinsonism with dopaminergic medications usually has an initial striking benefit in males and females with improved motor function, affect, appetite, and interest in activities, followed by equally consistent disabling motor fluctuations ("on-off" phenomena) and dyskinesias [<a class="bk_pop" href="#bpan.REF.hayflick.2013.1708">Hayflick et al 2013</a>, <a class="bk_pop" href="#bpan.REF.hogarth.2015.1">Hogarth 2015</a>].</p><p>As cognitive deficits progress in those with advanced disease, carbidopa/levodopa formulations may carry a lower risk of adverse neuropsychiatric effects than dopamine agonists. Amantadine may be helpful for dyskinesias, but also carries a risk (especially in higher doses) of adverse psychiatric effects such as hallucinations and agitation.</p><p>Pharmacologic treatment of dystonia and spasticity can include (if indicated) clonazepam or other benzodiazepines, oral baclofen, intramuscular botulinum toxin, and a trial of intrathecal baclofen. Trihexyphenydyl may also be useful for dystonia but may worsen cognitive dysfunction in advanced stages of the disease.</p></div><div id="bpan.SocialBehavioral_Concerns"><h4>Social/Behavioral Concerns</h4><p>Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and is typically performed one on one with a board-certified behavior analyst.</p><p>Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications when necessary.</p><p>Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.</p></div><div id="bpan.Other_Features_1"><h4>Other Features</h4><p><b>Disordered sleep.</b> Pharmacologic treatment of sleep abnormalities with melatonin, chloral hydrate, or benzodiazepines may be indicated.</p><p><b>Ophthalmologic findings.</b> Eye findings are treated in a routine manner.</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Use of a liquid nutritional supplement to help maintain weight as needed</div></li><li class="half_rhythm"><div>A gastric feeding tube to help maintain adequate weight (which becomes more difficult with disease progression) and to reduce the risk of aspiration pneumonia, if indicated</div></li><li class="half_rhythm"><div>Monitoring for complications of gastroesophageal reflux disease with institution of pharmacologic management if indicated. There are no data on the efficacy of fundoplication in BPAN.</div></li><li class="half_rhythm"><div>Over-the-counter fiber supplements and/or stool softeners to treat constipation, which is likely caused by a combination of immobility, diet, and medications</div></li><li class="half_rhythm"><div>Regular pulmonary hygiene to manage risk for pulmonary complications; tracheostomy as indicated when secretions are difficult to manage</div></li></ul></div></div><div id="bpan.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Routine follow up by a neurologist for medication management and interval assessment of ambulation, seizure activity, speech, and swallowing. Often done every three to six months, follow up may be annual for those who are more stable.</div></li><li class="half_rhythm"><div>For those receiving dopaminergic drugs (for parkinsonism), monitoring for adverse neuropsychiatric effects and disabling motor fluctuations and dyskinesias</div></li><li class="half_rhythm"><div>Follow-up ophthalmologic examination every one to two years</div></li></ul></div><div id="bpan.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#bpan.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="bpan.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Because women with mild manifestations of BPAN could potentially reproduce, the potential for teratogenic effects of medication taken during pregnancy needs to be considered.</p></div><div id="bpan.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Because BPAN falls in the category of <a href="/books/n/gene/nbia-ov/">NBIA</a> and because individuals with BPAN have high brain iron, the possibility of chelation therapy is sometimes raised. The chelator deferiprone is currently under investigation for treatment of another NBIA disorder, <a href="https://clinicaltrials.gov/ct2/show/NCT01741532?term=PKAN&#x00026;rank=2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PKAN</a>. However, to date there is no evidence that iron chelation initiated early in the disease course prevents or delays the parkinsonian degeneration in adulthood or otherwise alters the course of PKAN. Nonetheless, results of these studies may inform its use in BPAN and/or lead to additional clinical trials.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="bpan.Genetic_Counseling"><h2 id="_bpan_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="bpan.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Beta-propeller protein-associated neurodegeneration (BPAN) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. To date, most individuals with BPAN have been female. Data suggest that one male with BPAN had apparent <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>].</p></div><div id="bpan.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> To date, the vast majority of reported individuals with BPAN have been <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) and have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>Recommended parental <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> when a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an identified <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>:</p><ul><li class="half_rhythm"><div><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Molecular genetic testing of both parents</div></li><li class="half_rhythm"><div><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Molecular genetic testing of the mother only; the father of a male proband will neither have the disorder nor be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p>If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child and no other affected relatives, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> (and possibly somatic) <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>.</p><ul><li class="half_rhythm"><div>Presumed maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> has been reported in a family with two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>].</div></li><li class="half_rhythm"><div>In a second family, a phenotypically normal mother had the same <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as her sons with significant <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> skewed towards the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in her leukocyte DNA [<a class="bk_pop" href="#bpan.REF.dufke.2014">Dufke et al 2014</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> To date, nearly all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, suggesting a low risk to sibs.</p><ul><li class="half_rhythm"><div><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents.</div></li><li class="half_rhythm"><div><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother.</div></li></ul><p>If a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the parent's leukocyte DNA (female proband) or in the mother's leukocyte DNA (male proband), the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>].</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Females with the typical BPAN <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> do not reproduce. In rare cases, a female who is mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> may reproduce.</div><ul><li class="half_rhythm"><div>One very mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> female with somatic and, presumably, <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> has reproduced [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>]. The likelihood that a mildly affected female with somatic and germline mosaicism would transmit a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to offspring may be less than 50% [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>, <a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>]. However, the potential reduction in <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> is not quantifiable. Male fetuses are less likely to survive than female fetuses.</div></li><li class="half_rhythm"><div>One very mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> female with skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> in leukocyte DNA favoring the normal <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has reproduced [<a class="bk_pop" href="#bpan.REF.dufke.2014">Dufke et al 2014</a>]. In this instance, the chance to transmit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to offspring is 50%. A male conceptus may be less likely to survive.</div></li></ul></li><li class="half_rhythm"><div><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males do not reproduce.</div></li></ul><p><b>Other family members.</b> Given that most probands with BPAN reported to date have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to other family members is presumed to be low.</p></div><div id="bpan.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to parents of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="bpan.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>WDR45</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for BPAN are possible.</p></div></div><div id="bpan.Resources"><h2 id="_bpan_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>NBIA Alliance</b></div><div><b>Email:</b> Info@NBIAalliance.org</div><div><a href="http://www.nbiaalliance.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiaalliance.org</a></div></li><li class="half_rhythm"><div><b>NBIA Disorders Association</b></div><div>2082 Monaco Court</div><div>El Cajon CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> info@NBIAdisorders.org</div><div><a href="https://www.nbiadisorders.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiadisorders.org</a></div></li><li class="half_rhythm"><div><b>NBIA Disorders Association Research Registry and Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) Registry</b></div><div> CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> pwood@nbiadisorders.org</div><div><a href="http://www.nbiadisorders.org/research/patient-registry?highlight=YToxOntpOjA7czo4OiJyZWdpc3RyeSI7fQ==" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Patient Registry &#x00026; Biomaterial Bank</a></div></li><li class="half_rhythm"><div><b>NBIAcure</b></div><div>Center of Excellence for NBIA Clinical Care and Research</div><div>International Registry for NBIA and Related Disorders</div><div>Oregon Health &#x00026; Science University</div><div><b>Phone:</b> 503-494-4344</div><div><b>Fax:</b> 503-494-6886</div><div><b>Email:</b> gregorya@ohsu.edu</div><div><a href="http://nbiacure.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiacure.org</a></div></li><li class="half_rhythm"><div><b>Treat Iron-Related Childhood Onset Neurodegeneration (TIRCON) Registry</b></div><div>Germany</div><div><b>Phone:</b> 49-89-5160-7421</div><div><b>Fax:</b> 49-89-5160-7402</div><div><b>Email:</b> tircon@med.uni-muenchen.de</div><div><a href="http://tircon.eu/tircon-workpackages/wp1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://tircon.eu/tircon-workpackages/wp1</a></div></li></ul></div><div id="bpan.Molecular_Genetics"><h2 id="_bpan_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="bpan.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Beta-Propeller Protein-Associated Neurodegeneration: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK424403/table/bpan.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bpan.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_bpan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_bpan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_bpan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_bpan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_bpan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_bpan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/11152" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>WDR45</i></a></td><td headers="hd_b_bpan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=11152" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp11<wbr style="display:inline-block"></wbr>​.23</a></td><td headers="hd_b_bpan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9Y484" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WD repeat domain phosphoinositide-interacting protein 4</a></td><td headers="hd_b_bpan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=WDR45" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WDR45</a></td><td headers="hd_b_bpan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=WDR45[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">WDR45</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="bpan.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="bpan.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Beta-Propeller Protein-Associated Neurodegeneration (<a href="/omim/300526,300894" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK424403/table/bpan.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bpan.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300526" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300526</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">WD REPEAT-CONTAINING PROTEIN 45; WDR45</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300894" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300894</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>WDR45</i> contains 12 exons; the first two are non-coding. The longest transcript variant is <a href="/nuccore/NM_007075.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_007075.3</a>; a variant transcript <a href="/nuccore/NM_001029896.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001029896.1</a> has an alternate 5'UTR and lacks an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> three-nucleotide segment in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>, thus encoding a protein isoform with one less internal amino acid. See <a href="/books/NBK424403/#bpan.molgen.TA">Table A</a>, <b>Gene</b> for details on transcript variants.</p><p><b>Pathogenic variants.</b> Pathogenic variants have been documented in coding exons 3 to 12. All categories of variants have been reported including <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, and intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> (i.e., <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a>) (<a href="/books/NBK424403/#bpan.molgen.TA">Table A</a>, <b>HGMD</b>). Of note, a 3-bp <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletion has been reported in male/female sibs and their mother, who was mosaic for this variant [<a class="bk_pop" href="#bpan.REF.zarate.2016.1080">Zarate et al 2016</a>]. Apparent <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> was also found in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male [<a class="bk_pop" href="#bpan.REF.haack.2012.1144">Haack et al 2012</a>].</p><p>The majority of reported variants are predicted to be <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants [<a class="bk_pop" href="#bpan.REF.haack.2013.85">Haack et al 2013</a>]; the pathogenic basis for <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants and the 3-bp <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> are unclear.</p><p>Additionally, a 19.9-kb <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, non-mosaic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>WDR45</i> exons 3-12 as well as two adjacent genes <i>CCDC120</i> and <i>PRAF2</i> (partial and complete deletion, respectively) was reported in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male [<a class="bk_pop" href="#bpan.REF.abidi.2016.615">Abidi et al 2016</a>].</p><p>Nearly all pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>; most are unique and appear to occur across ethnic groups at the same frequency.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>WDR45</i> encodes WD repeat <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> phosphoinositide-interacting protein 4 (WIPI4), which has WD40 repeat units. WIPI4 is a member of a large family of proteins with repeating units containing a conserved core of 40+ amino acids that terminate with tryptophan-aspartate (W-D) residues [<a class="bk_pop" href="#bpan.REF.li.2001.2085">Li &#x00026; Roberts 2001</a>]. These proteins assume a highly symmetric, seven-bladed, beta-propeller platform structure; hence the name of the disorder, beta-propeller protein-associated neurodegeneration (BPAN). This structure supports specific protein-protein interactions and has a putative role in autophagy. Specifically WIPI4 is implicated in binding &#x02013; or associating &#x02013; with the known autophagy proteins ATG2A and ATG2B [<a class="bk_pop" href="#bpan.REF.proikascezanne.2004.9314">Proikas-Cezanne et al 2004</a>, <a class="bk_pop" href="#bpan.REF.behrends.2010.68">Behrends et al 2010</a>]; however, the exact role of <i>WDR45</i> in the autophagic process remains to be elucidated.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Lymphoblasts and brain tissue from individuals with <i>WDR45</i> pathogenic variants demonstrate evidence of dysregulation of autophagic flux [<a class="bk_pop" href="#bpan.REF.saitsu.2013.445">Saitsu et al 2013</a>, <a class="bk_pop" href="#bpan.REF.paudel.2015.39">Paudel et al 2015</a>]. A growing body of literature suggests dysregulation of autophagy as a mechanism in the pathophysiology of neurodegeneration [<a class="bk_pop" href="#bpan.REF.nassif.2012.78">Nassif &#x00026; Hetz 2012</a>]. In normal neurons, basal autophagy helps maintain protein quality control and organellar homeostasis. It has been proposed that injured or stressed cells rely on autophagy to clear damaged cell components and other by-products, and that neurons are particularly vulnerable to defects in autophagy because of the large expanse of dendritic and axonal cytoplasm that must be traversed in order to reach lysosomes concentrated near the cell body [<a class="bk_pop" href="#bpan.REF.nixon.2013.983">Nixon 2013</a>].</p></div><div id="bpan.References"><h2 id="_bpan_References_">References</h2><div id="bpan.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.abidi.2016.615">Abidi A, Mignon-Ravix C, Cacciagli P, Girard N, Milh M, Villard L. Early-onset epileptic encephalopathy as the initial clinical presentation of WDR45 deletion in a male patient. <span><span class="ref-journal">Eur J Hum Genet. </span>2016;<span class="ref-vol">24</span>:615–8.</span> [<a href="/pmc/articles/PMC4929878/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4929878</span></a>] [<a href="/pubmed/26173968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26173968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.behrends.2010.68">Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. <span><span class="ref-journal">Nature. </span>2010;<span class="ref-vol">466</span>:68–76.</span> [<a href="/pmc/articles/PMC2901998/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2901998</span></a>] [<a href="/pubmed/20562859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20562859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.dufke.2014">Dufke A, Grasshoff U, Dufke C, Kalscheuer V, Schroeder C, Beck-Wodl S, Tzschach A, Nagele T, Riess O, Bauer P, Krageloh-Mann I. NGS based whole X-exome analysis reveals a familial WDR45 missense mutation in 3 males with intellectual disability and brain iron accumulation. Abstract P08.53-S. Milan, Italy: European Society of Human Genetics Conference. 2014. Abstract available <a href="https://www.eshg.org/fileadmin/www.eshg.org/conferences/2014/ESHG2014Abstracts1.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>.</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.gregory.2011.254">Gregory A, Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. <span><span class="ref-journal">Curr Neurol Neurosci Rep. </span>2011;<span class="ref-vol">11</span>:254–61.</span> [<a href="/pmc/articles/PMC5908240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5908240</span></a>] [<a href="/pubmed/21286947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21286947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.gregory.2009.73">Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:73–80.</span> [<a href="/pmc/articles/PMC2675558/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2675558</span></a>] [<a href="/pubmed/18981035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18981035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.haack.2012.1144">Haack TB, Hogarth P, Kruer MC, Gregory A, Wieland T, Schwarzmayr T, Graf E, Sanford L, Meyer E, Kara E, Cuno SM, Harik SI, Dandu VH, Nardocci N, Zorzi G, Dunaway T, Tarnopolsky M, Skinner S, Frucht S, Hanspal E, Schrander-Stumpel C, H&#x000e9;ron D, Mignot C, Garavaglia B, Bhatia K, Hardy J, Strom TM, Boddaert N, Houlden HH, Kurian MA, Meitinger T, Prokisch H, Hayflick SJ. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">91</span>:1144–9.</span> [<a href="/pmc/articles/PMC3516593/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3516593</span></a>] [<a href="/pubmed/23176820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23176820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.haack.2013.85">Haack TB, Hogarth P, Gregory A, Prokisch H, Hayflick SJ. BPAN: the only X-linked dominant NBIA disorder. <span><span class="ref-journal">Int Rev Neurobiol. </span>2013;<span class="ref-vol">110</span>:85–90.</span> [<a href="/pubmed/24209435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24209435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.hayflick.2013.1708">Hayflick SJ, Kruer MC, Gregory A, Haack TB, Kurian MA, Houlden HH, Anderson J, Boddaert N, Sanford L, Harik SI, Dandu VH, Nardocci N, Zorzi G, Dunaway T, Tarnopolsky M, Skinner S, Holden KR, Frucht S, Hanspal E, Schrander-Stumpel C, Mignot C, H&#x000e9;ron D, Saunders DE, Kaminska M, Lin JP, Lascelles K, Cuno SM, Meyer E, Garavaglia B, Bhatia K, de Silva R, Crisp S, Lunt P, Carey M, Hardy J, Meitinger T, Prokisch H, Hogarth P. &#x003b2;-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:1708–17.</span> [<a href="/pmc/articles/PMC3673459/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3673459</span></a>] [<a href="/pubmed/23687123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23687123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.hogarth.2015.1">Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. <span><span class="ref-journal">J Mov Disord. </span>2015;<span class="ref-vol">8</span>:1–13.</span> [<a href="/pmc/articles/PMC4298713/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4298713</span></a>] [<a href="/pubmed/25614780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25614780</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.ichinose.2014.175">Ichinose Y, Miwa M, Onohara A, Obi K, Shindo K, Saitsu H, Matsumoto N, Takiyama Y. Characteristic MRI findings in beta-propeller protein-associated neurodegeneration (BPAN). <span><span class="ref-journal">Neurol Clin Pract. </span>2014;<span class="ref-vol">4</span>:175–7.</span> [<a href="/pmc/articles/PMC4001181/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4001181</span></a>] [<a href="/pubmed/24790802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24790802</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.khalifa.2015.381">Khalifa M, Naffaa L. Exome sequencing reveals a novel WDR45 frameshift mutation and inherited POLR3A heterozygous variants in a female with a complex phenotype and mixed brain MRI findings. <span><span class="ref-journal">Eur J Med Genet. </span>2015;<span class="ref-vol">58</span>:381–6.</span> [<a href="/pubmed/26096995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26096995</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.kruer.2012.407">Kruer MC, Boddaert N, Schneider SA, Houlden H, Bhatia KP, Gregory A, Anderson JC, Rooney WD, Hogarth P, Hayflick SJ. Neuroimaging features of neurodegeneration with brain iron accumulation. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2012;<span class="ref-vol">33</span>:407–14.</span> [<a href="/pubmed/21920862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21920862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.li.2001.2085">Li D, Roberts R. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. <span><span class="ref-journal">Cell Mol Life Sci. </span>2001;<span class="ref-vol">58</span>:2085–97.</span> [<a href="/pubmed/11814058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11814058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.long.2015.e714">Long M, Abdeen N, Geraghty MT, Hogarth P, Hayflick S, Venkateswaran S. Novel WDR45 mutation and pathognomonic BPAN imaging in a young female with mild cognitive delay. <span><span class="ref-journal">Pediatrics. </span>2015;<span class="ref-vol">136</span>:e714–7.</span> [<a href="/pubmed/26240209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26240209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.nakashima.2016.653">Nakashima M, Takano K, Tsuyusaki Y, Yoshitomi S, Shimono M, Aoki Y, Kato M, Aida N, Mizuguchi T, Miyatake S, Miyake N, Osaka H, Saitsu H, Matsumoto N. WDR45 mutations in three male patients with West syndrome. <span><span class="ref-journal">J Hum Genet. </span>2016;<span class="ref-vol">61</span>:653–61.</span> [<a href="/pubmed/27030146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27030146</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.nassif.2012.78">Nassif M, Hetz C. Autophagy impairment: a crossroad between neurodegeneration and tauopathies. <span><span class="ref-journal">BMC Biol. </span>2012;<span class="ref-vol">10</span>:78.</span> [<a href="/pmc/articles/PMC3448508/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3448508</span></a>] [<a href="/pubmed/22999309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22999309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.nishioka.2015.2004.e9">Nishioka K, Oyama G, Yoshino H, Li Y, Matsushima T, Takeuchi C, Mochizuki Y, Mori-Yoshimura M, Murata M, Yamasita C, Nakamura N, Konishi Y, Ohi K, Ichikawa K, Terada T, Obi T, Funayama M, Saiki S, Hattori N. High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism. <span><span class="ref-journal">Neurobiol Aging. </span>2015;<span class="ref-vol">36</span>:2004.e9–15.</span> [<a href="/pubmed/25744623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25744623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.nixon.2013.983">Nixon RA. The role of autophagy in neurodegenerative disease. <span><span class="ref-journal">Nat Med. </span>2013;<span class="ref-vol">19</span>:983–97.</span> [<a href="/pubmed/23921753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23921753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.ohba.2014.292">Ohba C, Nabatame S, Iijima Y, Nishiyama K, Tsurusaki Y, Nakashima M, Miyake N, Tanaka F, Ozono K, Saitsu H, Matsumoto N. De novo WDR45 mutation in a patient showing clinically Rett syndrome with childhood iron deposition in brain. <span><span class="ref-journal">J Hum Genet. </span>2014;<span class="ref-vol">59</span>:292–5.</span> [<a href="/pubmed/24621584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24621584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.paudel.2015.39">Paudel R, Li A, Wiethoff S, Bandopadhyay R, Bhatia K, de Silva R, Houlden H, Holton JL. Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy. <span><span class="ref-journal">Acta Neuropathol Commun. </span>2015;<span class="ref-vol">3</span>:39.</span> [<a href="/pmc/articles/PMC4486689/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4486689</span></a>] [<a href="/pubmed/26123052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26123052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.pellock.2010.2175">Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, Gaillard WD, Gibson PA, Holmes GL, Nordl DR, O'Dell C, Shields WD, Trevathan E, Wheless JW. Infantile spasms: a U.S. consensus report. <span><span class="ref-journal">Epilepsia. </span>2010;<span class="ref-vol">51</span>:2175–89.</span> [<a href="/pubmed/20608959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20608959</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.pontkingdon.2012.41">Pont-Kingdon G, Gedge F, Wooderchak-Donahue W, Schrijver I, Weck KE, Kant JA, Oglesbee D, Bayrak-Toydemir P, Lyon E, et al.  Design and analytical validation of clinical DNA sequencing assays. <span><span class="ref-journal">Arch Pathol Lab Med. </span>2012;<span class="ref-vol">136</span>:41–6.</span> [<a href="/pubmed/22208486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22208486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.proikascezanne.2004.9314">Proikas-Cezanne T, Waddell S, Gaugel A, Frickey T, Lupas A, Nordheim A. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. <span><span class="ref-journal">Oncogene. </span>2004;<span class="ref-vol">23</span>:9314–25.</span> [<a href="/pubmed/15602573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15602573</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.rathore.2014.574">Rathore GS, Schaaf CP, Stocco AJ. Novel mutation of the WDR45 gene causing beta-propeller protein-associated neurodegeneration. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:574–5.</span> [<a href="/pubmed/24610255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24610255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.saitsu.2013.445">Saitsu H, Nishimura T, Muramatsu K, Kodera H, Kumada S, Sugai K, Kasai-Yoshida E, Sawaura N, Nishida H, Hoshino A, Ryujin F, Yoshioka S, Nishiyama K, Kondo Y, Tsurusaki Y, Nakashima M, Miyake N, Arakawa H, Kato M, Mizushima N, Matsumoto N. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. <span><span class="ref-journal">Nat Genet. </span>2013;<span class="ref-vol">45</span>:445–9.</span> [<a href="/pubmed/23435086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23435086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.verhoeven.2014.332">Verhoeven WM, Egger JI, Koolen DA, Yntema H, Olgiati S, Breedveld GJ, Bonifati V, van de Warrenburg BP. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: novel mutations and neuropsychiatric phenotype in three adult patients. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2014;<span class="ref-vol">20</span>:332–6.</span> [<a href="/pubmed/24368176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24368176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bpan.REF.zarate.2016.1080">Zarate YA, Jones JR, Jones MA, Millan F, Juusola J, Vertino-Bell A, Schaefer GB, Kruer MC. Lessons from a pair of siblings with BPAN. <span><span class="ref-journal">Eur J Hum Genet. </span>2016;<span class="ref-vol">24</span>:1080–3.</span> [<a href="/pmc/articles/PMC5070893/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5070893</span></a>] [<a href="/pubmed/26577041" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26577041</span></a>]</div></li></ul></div></div><div id="bpan.Chapter_Notes"><h2 id="_bpan_Chapter_Notes_">Chapter Notes</h2><div id="bpan.Author_Notes"><h3>Author Notes</h3><p>The NBIAcure website, developed and maintained by Drs Susan Hayflick and Penny Hogarth and their team, contains up-to-date information about BPAN and the other NBIA disorders, geared for lay persons, clinicians, and researchers. Information about current research and opportunities to enroll online are available <a href="http://nbiacure.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a>.</p></div><div id="bpan.Acknowledgments"><h3>Acknowledgments</h3><p>Research reported in this publication was supported by a grant awarded to Dr Hogarth by the <i>National Center for Advancing Translational Sciences</i> of the National Institutes of Health under award number <i>UL1TR000128</i>. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></div><div id="bpan.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>16 February 2017 (bp) Review posted live</div></li><li class="half_rhythm"><div>9 February 2016 (ag) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK424403</span><span class="label">PMID: <a href="/pubmed/28211668" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">28211668</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bvd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/b-thal/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK424403&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK424403/?report=reader">PubReader</a></li><li><a href="/books/NBK424403/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK424403" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK424403" style="display:none" title="Cite this Page"><div class="bk_tt">Gregory A, Kurian MA, Haack T, et al. Beta-Propeller Protein-Associated Neurodegeneration. 2017 Feb 16. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK424403/pdf/Bookshelf_NBK424403.pdf">PDF version of this page</a> (936K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#bpan.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#bpan.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#bpan.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#bpan.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#bpan.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#bpan.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#bpan.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#bpan.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#bpan.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#bpan.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#bpan.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=11152[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">WDR45</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4382412" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4382412" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4382412" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4382412" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27905812" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">STXBP1</i> Encephalopathy with Epilepsy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">STXBP1</i> Encephalopathy with Epilepsy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Khaikin Y, Mercimek-Mahmutoglu S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24278995" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moog U, Uyanik G, Kutsche K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301494" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SCN1A</i> Seizure Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SCN1A</i> Seizure Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Miller IO, Sotero de Menezes MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=28211668" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=28211668" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f2575f66d18aab73d5a">Beta-Propeller Protein-Associated Neurodegeneration - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Beta-Propeller Protein-Associated Neurodegeneration - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:38:45-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DF4AFE03F1C11000000000A5403A0&amp;ncbi_session=CE8DF4AFE040F251_2644SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK424403%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK424403&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK424403/&amp;ncbi_pagename=Beta-Propeller Protein-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DF4AFE040F251_2644SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>